1. Volume 10, Issue 4, Pages 320-328 (April 2011)
Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT- TRAUK): a double-blind randomised trial 
Dr Davide Pareyson, MD, Prof Mary M Reilly, FRCP, Angelo Schenone, MD, Gian Maria Fabrizi, MD, Tiziana Cavallaro, MD, Prof Lucio Santoro, MD, Prof Giuseppe Vita, MD, Prof Aldo Quattrone, MD, Luca Padua, MD, Franco Gemignani, MD, Francesco Visioli, PhD, Matilde Laurà, MD, Davide Radice, MSc, Daniela Calabrese, MSc, Prof Richard AC Hughes, FRCP, Alessandra Solari, MD 
The Lancet Neurology 
Volume 10, Issue 4, Pages (April 2011)
DOI: /S (11)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile *Consent withdrawn before start of treatment.
The Lancet Neurology  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2 Mean CMTNS (A) and mean change in CMTNS from baseline (B)
Analysis was done on all patients who were randomised and received at least one dose of study drug. Higher CMTNS indicates more severe disease. CMTNS=Charcot–Marie–Tooth neuropathy score.
The Lancet Neurology  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions